HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.

Abstract
A prospective study of renal osteodystrophy in moderate renal insufficiency was undertaken to assess the effects of 25(OH)D3 (Calcifediol) on healing of bone lesions and improvement of linear growth. One year after entering the study, the mean group growth velocity increased into the normal range and remained there in the next two therapy years. A significant correlation existed between pretherapy and one-year therapy values of growth velocity and serum 25(OH)D3 concentration. Qualitative bone histology obtained by transilial bone biopsy was also evaluated during the course of study. Catch-up growth was not seen, but potential for such growth may exist in later years in our patients.
AuthorsC B Langman, A T Mazur, R Baron, M E Norman
JournalThe Journal of pediatrics (J Pediatr) Vol. 100 Issue 5 Pg. 815-20 (May 1982) ISSN: 0022-3476 [Print] United States
PMID7069549 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hydroxycholecalciferols
Topics
  • Child
  • Child, Preschool
  • Chronic Kidney Disease-Mineral and Bone Disorder (complications, drug therapy)
  • Growth (drug effects)
  • Humans
  • Hydroxycholecalciferols (blood, therapeutic use)
  • Kidney Failure, Chronic (complications)
  • Male
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: